NAC: CHAPTER 453 - CONTROLLED SUBSTANCES

[Rev. 11/6/2023 10:59:05 AM]

[NAC-453 Revised Date: 10-23]

CHAPTER 453 - CONTROLLED SUBSTANCES

GENERAL PROVISIONS

453.010 Definitions.

453.015 “Directions for use” interpreted.

453.020 “Facsimile machine” interpreted.

COMPUTERIZED PROGRAM TO TRACK PRESCRIPTIONS FOR CONTROLLED SUBSTANCES

453.065 Internet access to database: Application for enrollment by registrants and law enforcement employees; access to patient utilization report by law enforcement employee without enrollment; access is revocable privilege.

453.067 Internet access to database: Application by certain practitioners who are not licensed in this State; required course of training; designation of delegate prohibited.

453.068 Provision of access to database to certain authorized persons.

453.070 Designation by practitioner of staff members to act as delegates for accessing database on behalf of practitioner; exception; required course of training; liability and duties of practitioner.

453.072 Designation by managing pharmacist of certain employees to act as delegates for accessing database on behalf of pharmacy; required course of training; liability and duties of managing pharmacist.

453.074 Designation by hospital of staff members to act as delegates for accessing database on behalf of physician in emergency department; required course of training; liability and duties of hospital.

453.075 Duties of practitioner whose records are integrated with patient records in database; certain delegates prohibited from accessing database using electronic health records.

453.076 Adoption of user support manual by reference; revision after adoption; duty of persons with access to database to read and comply with manual.

453.078 Suspension or termination of access to database.

453.084 Notice of suspension or termination of access to database; hearing; request for continuance.

453.088 Restriction on disclosure of information obtained from database.

REGISTRATION

453.100 Exemption from registration.

453.105 Law enforcement officer authorized to register for purpose of possessing controlled substances in training of canine; registration not required.

453.110 Groups of activities involving controlled substances: Independent activities requiring separate registration; substances included in registration.

453.120 Groups of activities involving controlled substances: Coincident activities authorized without additional registration.

453.130 Physical locations of activities.

453.140 Federally exempted officials engaged in private activities.

453.150 Waiver of registration: Drug enforcement officers and employees.

453.160 Waiver of registration: Civil defense and disaster relief organizations.

453.190 Payment of fees for registration.

453.210 Period for application; restriction on activities for which registration is required; expiration and renewal of registration.

453.220 Application forms for registration and reregistration.

453.230 Filing of application for registration.

453.240 Acceptance of application for registration.

453.250 Submission of documents with application for registration.

453.260 Amendment or withdrawal of application for registration.

453.270 Issuance and content of certificate of registration; display by registrant; issuance of duplicate certificate of registration.

453.280 Modification of registration.

453.285 Placement of registration on inactive status: Grounds; effect; duration; notice; reinstatement; appeal.

453.290 Suspension or revocation of registration.

453.300 Inspections of premises.

CONTROL

453.400 Security of controlled substances.

453.410 Dispensing of controlled substances by practitioner.

453.420 Dispensing of schedule II controlled substance in emergency.

453.430 Restrictions on issuance of prescriptions; continuation of dependency on narcotic drug authorized under certain circumstances.

453.440 Prescriptions: Contents; additions and changes.

453.450 Prescriptions for schedule II controlled substances.

453.460 Partial filling of prescription.

453.470 Information to be affixed to package for prescription.

453.475 Initial and biennial inventory of controlled substances by new managing pharmacist.

453.480 Maintenance of files of prescriptions.

453.485 Records to be maintained by pharmacist.

453.488 Lost or stolen order forms.

453.490 Dispensing of controlled substances which are not prescription drugs.

SCHEDULES OF CONTROLLED SUBSTANCES

453.510 Schedule I.

453.520 Schedule II.

453.530 Schedule III.

453.540 Schedule IV.

453.550 Schedule V.

PROGRAM TO RESEARCH THERAPEUTIC EFFECTS OF MARIJUANA

453.740 Protocols of research and treatment.

GENERAL PROVISIONS

NAC 453.010 Definitions. (NRS 453.221, 453.256, 639.070) As used in this chapter, unless the context otherwise requires:

1. “Board” means the State Board of Pharmacy.

2. “Emergency situation,” within the meaning of subsection 2 of NRS 453.256 and these regulations, means a situation in which a prescribing practitioner determines that:

(a) Immediate administration of the controlled substance is necessary for the proper treatment of the patient;

(b) No appropriate alternative treatment is available, including administration of a drug which is not a controlled substance under schedule II of the Uniform Controlled Substances Act; and

(c) It is not reasonably possible for the prescribing practitioner to provide a written prescription to be presented to the person dispensing the substance before he or she dispenses it.

[Bd. of Pharmacy, § 453.010, eff. 6-26-80]

NAC 453.015 “Directions for use” interpreted. (NRS 453.221, 639.070) As the term is used in NRS 453.385, 639.2353 and 639.2801 and NAC 453.410, the Board interprets “directions for use” to require a prescription or label to specify the dosage, frequency and manner in which the prescribed controlled substance is to be taken or applied, unless the dosage, frequency and manner in which the prescribed controlled substance is to be taken or applied are specifically described on or in the manufacturer’s individual packages or containers for the prescribed controlled substance. Use of the phrase “take as directed” or any phrase of similar import does not satisfy the requirements set forth in this section.

(Added to NAC by Bd. of Pharmacy, eff. 9-29-87)

NAC 453.020 “Facsimile machine” interpreted. (NRS 453.221, 453.256, 453.385, 639.070) As used in NRS 453.256 and 453.385, the Board will interpret the term “facsimile machine” to include, without limitation, a computer that has a facsimile modem through which documents can be sent and received.

(Added to NAC by Bd. of Pharmacy by R112-99, eff. 11-3-99)

COMPUTERIZED PROGRAM TO TRACK PRESCRIPTIONS FOR CONTROLLED SUBSTANCES

NAC 453.065 Internet access to database: Application for enrollment by registrants and law enforcement employees; access to patient utilization report by law enforcement employee without enrollment; access is revocable privilege. (NRS 453.162, 453.165, 453.221, 639.070, 639.23916)

1. A practitioner or other person who is required to register with the Board pursuant to subsection 1 of NRS 453.226 to dispense controlled substances must also enroll with the Board pursuant to this section for Internet access to the database of the computerized program established pursuant to NRS 453.162.

2. An employee of a law enforcement agency who intends to regularly access the database of the computerized program established pursuant to NRS 453.162 for the purposes described in NRS 453.165 may enroll with the Board pursuant to this section.

3. To enroll pursuant to this section for Internet access to the database of the computerized program established pursuant to NRS 453.162, the practitioner or other person or employee of a law enforcement agency must apply to the Board on an application provided by the Board. For purposes of subsection 1 of NRS 453.226, the Board will deem such enrollment as proof that the practitioner or other person is authorized to access the database. An application submitted by an employee of a law enforcement agency pursuant to this subsection must be accompanied by the certification required by subsection 2 of NRS 453.165.

4. An employee of a law enforcement agency who is not enrolled pursuant to this section may obtain a patient utilization report pursuant to NRS 639.23507 or a summary of a practitioner’s prescribing history from the database of the computerized program established pursuant to NRS 453.162 for use in an investigation if he or she submits the certification required by subsection 2 of NRS 453.165.

5. Access to the database of the computerized program established pursuant to NRS 453.162 is a revocable privilege, and no holder of such access to the database acquires any vested right therein or thereunder.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018; A by R008-21, 12-22-2021)

NAC 453.067 Internet access to database: Application by certain practitioners who are not licensed in this State; required course of training; designation of delegate prohibited. (NRS 453.221, 639.070)

1. A physician, dentist, podiatric physician, advanced practice registered nurse, physician assistant or optometrist who is not licensed to practice in this State but is authorized to prescribe a controlled substance pursuant to 21 C.F.R. § 1306.03 or a pharmacist who is not licensed to practice in this State but is authorized to dispense a controlled substance pursuant to 21 C.F.R. § 1306.06 may apply to the Board on a form prescribed by the Board for Internet access to the database of the computerized program established pursuant to NRS 453.162 to obtain patient utilization reports for patients to whom they prescribe or dispense a controlled substance.

2. Before a person described in subsection 1 may receive Internet access to the database, he or she must complete the course of training developed pursuant to NRS 453.164. Such a person is subject to the laws and regulations of this State relating to the database.

3. A person described in subsection 1 who receives Internet access to the database of the computerized program established pursuant to NRS 453.162 may not designate a delegate pursuant to NAC 453.070.

(Added to NAC by Bd. of Pharmacy by R035-19, eff. 2-7-2020)

NAC 453.068 Provision of access to database to certain authorized persons. (NRS 453.162, 639.070, 639.23916) The Board will provide Internet access to the database of the computerized program established pursuant to NRS 453.162 for the purpose of obtaining patient utilization reports to:

1. Employees of the United States Department of Veterans Affairs who are authorized to access such reports under the provisions of 38 U.S.C. § 1730B;

2. Persons who are authorized to access such a report under Medicaid pursuant to 42 U.S.C. § 1396r-8(g) or 1396w-3a; and

3. Persons who are authorized to access reports under the provisions of a written agreement entered into pursuant to subsection 2 of NRS 453.163.

(Added to NAC by Bd. of Pharmacy by R008-21, eff. 12-22-2021)

NAC 453.070 Designation by practitioner of staff members to act as delegates for accessing database on behalf of practitioner; exception; required course of training; liability and duties of practitioner. (NRS 453.221, 639.070, 639.23916)

1. Except as otherwise provided in NAC 453.074, a practitioner other than a veterinarian may designate not more than two members of his or her staff to act as delegates for the purpose of accessing the database of the computerized program established pursuant to NRS 453.162 to obtain a patient utilization report pursuant to NRS 639.23507 on behalf of the practitioner.

2. A delegate designated pursuant to subsection 1 must complete the course of training developed pursuant to subsection 5 of NRS 453.164 before the delegate is provided with Internet access to the database.

3. The practitioner shall be liable for any action of the delegate relating to accessing the database.

4. The practitioner must:

(a) Immediately notify the Board when a delegate ceases to be a member of the staff of the practitioner; and

(b) Cooperate with the Board to take any action necessary to terminate the access of the delegate to the database.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018; A by R035-19, 2-7-2020)

NAC 453.072 Designation by managing pharmacist of certain employees to act as delegates for accessing database on behalf of pharmacy; required course of training; liability and duties of managing pharmacist. (NRS 453.163, 453.221, 639.070)

1. A managing pharmacist pursuant to NRS 639.220 may designate an intern pharmacist, pharmaceutical technician or pharmaceutical technician in training employed by the pharmacy to act as a delegate to access the database of the computerized program established pursuant to NRS 453.162 on behalf of the pharmacy.

2. A delegate designated pursuant to subsection 1 must complete the course of training developed pursuant to subsection 5 of NRS 453.164 before the delegate is provided Internet access to the database.

3. The managing pharmacist shall be liable for any action of the delegate designated pursuant to subsection 1 relating to accessing the database.

4. The managing pharmacist must:

(a) Immediately notify the Board when a delegate designated pursuant to subsection 1 ceases to be employed by the pharmacy; and

(b) Cooperate with the Board to take any action necessary to terminate the access of the delegate to the database.

5. As used in this section:

(a) “Intern pharmacist” has the meaning ascribed to it in NRS 639.0086.

(b) “Managing pharmacist” has the meaning ascribed to it in NRS 639.0087.

(d) “Pharmaceutical technician in training” has the meaning ascribed to it in NRS 639.0115.

(Added to NAC by Bd. of Pharmacy by R035-19, eff. 2-7-2020)

NAC 453.074 Designation by hospital of staff members to act as delegates for accessing database on behalf of physician in emergency department; required course of training; liability and duties of hospital. (NRS 453.221, 639.070, 639.23507)

1. A hospital may designate members of the staff of the hospital to act as delegates for the purpose of accessing the database of the computerized program established pursuant to NRS 453.162 to obtain a patient utilization report pursuant to NRS 639.23507 on behalf of a physician providing service in a hospital emergency department.

3. The hospital shall be liable for any action of the delegate relating to accessing the database.

4. The hospital must:

(a) Immediately notify the Board whenever a delegate ceases to be a member of the staff of the hospital; and

(b) Cooperate with the Board to take any action necessary to terminate the access of the delegate to the database.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018; A by R035-19, 2-7-2020)

NAC 453.075 Duties of practitioner whose records are integrated with patient records in database; certain delegates prohibited from accessing database using electronic health records. (NRS 453.162, 639.070, 639.23916)

1. A practitioner whose electronic health records are integrated with the records of patients in the database of the computerized program established pursuant to NRS 453.162 shall:

(a) Maintain the electronic health records in conformance with all applicable federal and state laws;

(b) Maintain a record of access to the database of the computerized program and the retrieval of patient utilization reports from that database; and

(c) Retain the records described in paragraph (b) as a health care record in accordance with NRS 629.051 to 629.069, inclusive, in a manner that is easily retrievable upon the request of the Board or a representative thereof.

2. A person designated as a delegate pursuant to NAC 453.070, 453.072 or 453.074 is not authorized to access the database of the computerized program established pursuant to NRS 453.162 using electronic health records.

3. As used in this section, “electronic health record” has the meaning ascribed to it in NRS 453.162.

(Added to NAC by Bd. of Pharmacy by R008-21, eff. 12-22-2021)

NAC 453.076 Adoption of user support manual by reference; revision after adoption; duty of persons with access to database to read and comply with manual. (NRS 453.162, 639.070, 639.23916)

1. The PMP AWARxE Requestor User Support Manual: Nevada Prescription Monitoring Program, published by Appriss Health, is hereby adopted by reference. A copy of the publication is available, free of charge, from the Board at the Internet address https://bop.nv.gov/uploadedFiles/bopnvgov/content/Links/NV%20Requestor%20User%20Support%20Manual_v2.1_020921_FINAL.pdf.

2. The Board will periodically review the publication adopted by reference in subsection 1 and determine, within 120 days after the review, whether any change made to the publication is appropriate for application in this State. If the Board does not disapprove a change to the publication within 120 days after the review, the change is deemed to be approved by the Board.

3. Each person required or authorized to receive Internet access to the database of the computerized program pursuant to NRS 453.164, 453.1645 or 453.165:

(a) Must read the publication adopted by reference in subsection 1 before the Board will provide the person with Internet access to the database. Compliance with this paragraph satisfies the requirement prescribed by subsection 5 of NRS 453.164 to complete a course of training developed by the Board and the Division.

(b) Shall comply with the publication adopted by reference in subsection 1 when using the database.

(Added to NAC by Bd. of Pharmacy by R008-21, eff. 12-22-2021)

NAC 453.078 Suspension or termination of access to database. (NRS 453.221, 639.070)

1. The Executive Secretary of the Board on behalf of the Board may suspend or terminate, before a hearing, the Internet access of a practitioner or other person to the database of the program established pursuant to NRS 453.162 if the practitioner or other person accesses the database in violation of any provision of NRS 453.162 to 453.165, inclusive, 639.23507 or 639.23915.

2. As used in this section, “practitioner” does not include a hospital or other institution which is licensed, registered or otherwise authorized in this State to distribute, dispense, conduct research with respect to, administer or use in teaching or chemical analysis a controlled substance in the course of professional practice or research.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018)

NAC 453.084 Notice of suspension or termination of access to database; hearing; request for continuance. (NRS 453.221, 639.070)

1. If Internet access to the database of the program established pursuant to NRS 453.162 is suspended or terminated pursuant to NAC 453.078, the Board will provide written notice to the practitioner or other person whose Internet access to the database of the program is suspended or terminated:

(a) If practicable, before the suspension or termination occurs; or

(b) If notice cannot be provided before the suspension or termination occurs, as soon as practicable after the suspension or termination occurs.

2. In the event of a suspension or termination of Internet access to the database of the program pursuant to NAC 453.078, the Board will conduct a hearing at the next regularly scheduled meeting of the Board, but in any event, the hearing must be instituted and determined within 45 days after the date of the suspension or termination unless a continuance is requested by the practitioner or other person whose Internet access to the database of the program is suspended or terminated.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018)

NAC 453.088 Restriction on disclosure of information obtained from database. (NRS 453.221, 639.070) The Board will disclose information obtained from the database in response to a request made pursuant to paragraph (a) of subsection 8 of NRS 453.164 only to the person about whom the information requested concerns or his or her attorney.

(Added to NAC by Bd. of Pharmacy by R013-18, eff. 6-26-2018)

REGISTRATION

NAC 453.100 Exemption from registration. (NRS 453.221, 453.226, 639.070) Any person exempted from federal registration by federal laws or regulations is exempted from registration under this chapter. The burden of establishing entitlement to an exemption is upon the claimant.

[Bd. of Pharmacy, § 453.020, eff. 6-26-80]

NAC 453.105 Law enforcement officer authorized to register for purpose of possessing controlled substances in training of canine; registration not required. (NRS 453.221, 453.226, 639.070)

1. Notwithstanding the exemption from registration set forth in NAC 453.100 and the waiver of the requirement of registration set forth in NAC 453.150, a law enforcement officer who is employed by the State or any of its political subdivisions or agencies may register pursuant to this chapter for the purpose of possessing controlled substances in the course of training a canine to detect a controlled substance.

2. Nothing in this section shall be construed to require a law enforcement officer to register before:

(a) Possessing a controlled substance in order to train a canine to detect the controlled substance; or

(b) Engaging in any other conduct for which the law enforcement officer is otherwise authorized to perform without a registration.

(Added to NAC by Bd. of Pharmacy by R050-22, eff. 9-28-2022)

NAC 453.110 Groups of activities involving controlled substances: Independent activities requiring separate registration; substances included in registration. (NRS 453.221, 453.226, 639.070)

1. For the purpose of registration under this chapter, the following groups of activities are deemed to be independent of each other:

(a) Manufacturing any controlled substance;

(b) Distributing any controlled substance;

(c) Dispensing, prescribing, conducting research, except for the research described in paragraph (d), and conducting instructional activities with any controlled substance listed in schedules II through V, inclusive;

(d) Conducting research with any narcotic drug listed in schedules II to V, inclusive, for the purpose of continuing the dependence of a person on the drug in the course of conducting an authorized clinical investigation in the development of a program for rehabilitation of persons with a narcotic use disorder pursuant to a Notice of Claimed Investigational Exemption for a New Drug approved by the Food and Drug Administration;

(e) Conducting research and instructional activities with any controlled substances listed in schedule I;

(f) Conducting chemical analysis with a controlled substance listed in any schedule; and

(g) Possessing any controlled substance in the course of training canines to detect a controlled substance by a law enforcement officer who is registered pursuant to NAC 453.105.

2. A person who engages in more than one group of independent activities must obtain a separate registration for each group of activities except as provided in NAC 453.120.

3. Except as otherwise provided in subsection 4, a single registration to engage in any group of independent activities may include one or more of the controlled substances listed in the schedules which are authorized for that group.

4. A person registered to conduct research with the controlled substances listed in schedule I may conduct research with any substance listed in schedule I for which he or she has filed and had approved a research protocol.

[Bd. of Pharmacy, § 453.030, eff. 6-26-80]—(NAC A by R050-22, 9-28-2022)

NAC 453.120 Groups of activities involving controlled substances: Coincident activities authorized without additional registration. (NRS 453.221, 453.226, 639.070) Any person who is registered to engage in any activity described in NAC 453.110 may engage in the following coincident activities without obtaining a registration to engage in the coincident activities if, unless specifically exempted, the person complies with all the requirements and duties prescribed by law for persons registered to engage in the coincident activities:

1. A person registered to manufacture any controlled substance or basic class of controlled substances may distribute that substance or class but no substance or class which the person is not registered to manufacture.

2. A person registered to manufacture a controlled substance listed in schedules II to V, inclusive, may conduct chemical analysis and preclinical research (including analysis for control of quality) with the controlled substances which the person is authorized to manufacture.

3. A person registered to conduct research with a basic class of controlled substances listed in schedule I may:

(a) Manufacture the substances in the class, if and to the extent that the manufacture is described in his or her federal research protocol; and

(b) Distribute substances in the class to other persons registered to conduct research or chemical analysis with the class.

4. A person registered to conduct chemical analysis with controlled substances may:

(a) Manufacture and import the substances for analytical or instructional purposes;

(b) Distribute the substances to other persons registered to conduct chemical analysis or instructional activities, to persons registered or authorized to conduct research with such substances and to persons exempted from registration;

(c) Export the substances to persons in other countries performing chemical analysis or enforcing laws relating to controlled substances or drugs in those countries; and

(d) Conduct instructional activities with controlled substances.

5. A person registered or authorized to conduct research, except for the research described in paragraph (d) of subsection 1 of NAC 453.110, with controlled substances listed in schedules II to V, inclusive, may:

(a) Conduct chemical analysis with the substances listed in those schedules for the purpose of research into the manufacture of the substances if and to the extent that the research into manufacture is set forth in a statement filed with the person’s application for federal registration;

(b) Distribute the substances to other persons registered or authorized to conduct chemical analysis, instructional activities or research with the substances, and to persons exempted from registration; and

6. A person registered to prescribe, dispense or, except for the research described in paragraph (d) of subsection 1 of NAC 453.110, conduct research with the controlled substances listed in schedules II through V may also conduct instructional activities with those substances.

[Bd. of Pharmacy, § 453.030, eff. 6-26-80]

NAC 453.130 Physical locations of activities. (NRS 453.221, 453.226, 639.070) A separate registration is required for each principal place of business or professional practice at one general location where controlled substances are manufactured, distributed, used in research or scientific investigation, prescribed or dispensed. The following locations are not required to be registered:

1. A warehouse where controlled substances are stored by or on behalf of a registered person unless the substances are distributed directly:

(a) From the warehouse to registered locations other than the registered location from which the substances were delivered; or

(b) To persons who are exempt from registration by paragraph (b) of subsection 3 of NRS 453.226.

2. A sales office which:

(a) Is used by agents of a registrant for the solicitation and sale of controlled substances; and

(b) Does not contain controlled substances other than substances for display purposes or lawful distribution as samples only, and is not used as a distribution point for filling sales orders.

3. A practitioner’s office:

(a) Which is used by a practitioner (who is registered at another location) to prescribe controlled substances but not to administer or otherwise dispense them as a regular part of his or her professional practice at that office; and

(b) Where no supplies of controlled substances are maintained.

[Bd. of Pharmacy, § 453.040, eff. 6-26-80]

NAC 453.140 Federally exempted officials engaged in private activities. (NRS 453.221, 453.226, 639.070) If any official exempted from federal registration by federal law also engages as a private person in any activity or group of activities for which registration in this State is required, the official must obtain a registration pursuant to these regulations for the private activities.

[Bd. of Pharmacy, § 453.080, eff. 6-26-80]

NAC 453.150 Waiver of registration: Drug enforcement officers and employees. (NRS 453.221, 453.226, 639.070)

1. The requirement of registration is waived for:

(a) An officer or employee of:

(1) The United States Drug Enforcement Administration;

(2) The United States Bureau of Customs;

(3) The United States Food and Drug Administration; and

(4) Any other federal officer who is lawfully engaged in the enforcement of any federal law relating to controlled substances, drugs or customs and is authorized to possess controlled substances in the course of his or her official duties.

(b) An officer or employee of this State or any of its political subdivisions or agencies who is engaged in the enforcement of any state or local law relating to controlled substances and is authorized to possess controlled substances in the course of his or her official duties.

2. An official exempted by this regulation may:

(a) When acting in the course of his or her official duties, possess any controlled substance and distribute any such substance to any other official who is also exempted by this regulation and acting in the course of his or her official duties.

(b) Procure any controlled substance in the course of an inspection or in the course of any criminal investigation involving the person from whom the substance was procured.

3. A laboratory of a law enforcement agency which obtains and transfers controlled substances for use as standards in chemical analysis must annually obtain a registration to conduct chemical analysis. Such a laboratory is exempt from payment of a fee for the registration. Laboratory employees, when acting in the scope of their official duties, are deemed to be officials exempted by this regulation. For purposes of this subsection, laboratory activities do not include field or other preliminary chemical tests by officials exempted by this regulation.

[Bd. of Pharmacy, § 453.050, eff. 6-26-80]

NAC 453.160 Waiver of registration: Civil defense and disaster relief organizations. (NRS 453.221, 453.226, 639.070)

1. The requirement of registration is waived for any official of an organization for civil defense or disaster relief who, in the course of his or her official duties, is authorized to:

(a) Maintain, and distribute for maintenance, controlled substances for emergency use; or

(b) Procure controlled substances for the purpose of maintaining supplies for emergency use if the procurement is from the United States General Services Administration and in accordance with the rules of the United States Office of Emergency Preparedness.

2. The requirement of registration is waived for any official of an organization for civil defense or disaster relief during a state of emergency or disaster which is within the official’s jurisdiction and has been so proclaimed by the President or by a concurrent resolution of Congress. In the course of his or her official duties during such an emergency or disaster, the official may:

(a) Dispense controlled substances; or

(b) Procure or distribute controlled substances if the procurement is on a special Civil Defense Emergency Order Form furnished by the United States Office of Emergency Preparedness.

3. A Civil Defense Emergency Order Form may be used and is valid only during a state of emergency or disaster proclaimed by the President or by a concurrent resolution of Congress for the area in which the organization using the form has jurisdiction. The person who completes the form shall state the name of the organization for civil defense or disaster relief, his or her position and the nature and legal designation of the emergency or disaster. The form may be completed by any person registered under the Controlled Substances Act.

[Bd. of Pharmacy, § 453.060, eff. 6-26-80]

NAC 453.190 Payment of fees for registration. (NRS 453.221, 453.226, 639.070) The fee for registration or reregistration must be paid when the application for registration or reregistration is submitted for filing. The payment must be made by a personal, certified or cashier’s check, a credit card, a debit card, an electronic transfer of money or a money order payable to the State Board of Pharmacy. Any attempted payment made in the form of stamps, foreign currency or an endorsed check of a third person will not be accepted.

[Bd. of Pharmacy, § 453.100, eff. 6-26-80]—(NAC A by R033-19, 2-7-2020)

NAC 453.210 Period for application; restriction on activities for which registration is required; expiration and renewal of registration. (NRS 453.221, 453.226, 639.070)

1. A person who is required to be registered:

(a) May apply for registration at any time.

(b) Shall not engage in any activity for which registration is required until his or her application for registration is granted and a certificate of registration is issued to the person by the Board.

2. A person who is registered may renew his or her registration biennially by submitting an application for renewal and paying the renewal fee.

3. All registrations expire on October 31 of each even-numbered year.

[Bd. of Pharmacy, § 453.120, eff. 6-26-80]—(NAC A 1-10-94)

NAC 453.220 Application forms for registration and reregistration. (NRS 453.221, 453.226, 639.070)

1. An application for registration or reregistration must be made on the form provided by the Board.

2. An application for registration or reregistration to:

(a) Conduct research with any of the controlled substances listed in schedule I must be accompanied by evidence of a current federal registration to conduct such research, together with a copy of the applicant’s federal research protocol.

(b) Conduct instructional activities with controlled substances listed in schedule I must be accompanied by a copy of any statement filed in support of an application for federal registration. Each application must include each item of information required in the form. If an item is not applicable, this fact must be stated.

[Bd. of Pharmacy, § 453.130, eff. 6-26-80]

NAC 453.230 Filing of application for registration. (NRS 453.221, 453.226, 639.070)

1. All applications for registration must be submitted for filing to the Secretary of the Board. The appropriate registration fee and any required attachments must accompany the application.

2. Any person required to obtain more than one registration may submit all the applications together. Each application must be complete and must not refer to any accompanying application for required information.

[Bd. of Pharmacy, § 453.140, eff. 6-26-80]

NAC 453.240 Acceptance of application for registration. (NRS 453.221, 453.226, 639.070)

1. Each application submitted for filing will be dated upon receipt. If an application is complete, it will be accepted for filing, but any application which fails to comply with the requirements of these regulations will not be accepted for filing. If an application has a minor defect of incompleteness, the Secretary of the Board may accept it for filing and request the applicant to furnish additional information.

2. A defective application:

(a) Will be returned to the applicant within 10 days after its receipt and will be accompanied by a statement of the reason for its return.

(b) May be corrected and resubmitted for filing at any time and the Secretary of the Board will accept the resubmitted application for filing if the defect is corrected.

3. The Secretary’s acceptance of an application for filing does not preclude any subsequent request for additional information, and has no bearing on whether the application will be granted.

[Bd. of Pharmacy, § 453.150, eff. 6-26-80]

NAC 453.250 Submission of documents with application for registration. (NRS 453.221, 453.226, 639.070) The Board may require an applicant to submit such documents or written statement of fact relevant to the application as it deems necessary to determine whether the application should be granted. The failure of the applicant to provide documents or statements within 30 days after being requested to do so shall be deemed to be a waiver by the applicant of an opportunity to present those documents or facts for consideration by the Board in granting or denying the application.

[Bd. of Pharmacy, § 453.160, eff. 6-26-80]

NAC 453.260 Amendment or withdrawal of application for registration. (NRS 453.221, 453.226, 639.070)

1. An application may be amended or withdrawn at any time with the permission of the Board if good cause is shown by the applicant or if the amendment or withdrawal is in the public interest.

2. After an application has been accepted for filing, the request by the applicant that it be returned, or the failure of the applicant to respond to official correspondence regarding the application when sent by registered or certified mail with return receipt requested, shall be deemed to be a withdrawal of the application.

[Bd. of Pharmacy, § 453.170, eff. 6-26-80]

NAC 453.270 Issuance and content of certificate of registration; display by registrant; issuance of duplicate certificate of registration. (NRS 453.221, 639.070)

1. The certificate of registration will set forth the name, address and registration number of the registrant, the activity authorized by the registration, the schedules of the controlled substances which the registrant is authorized to handle and the amount of the fee paid or a notation that the registrant is exempted from the fee.

2. The registrant shall prominently display the certificate of registration at the registered location.

3. Upon the request of a registrant, the Board will issue to the registrant a duplicate certificate of registration.

[Bd. of Pharmacy, § 453.190, eff. 6-26-80]—(NAC A 11-9-95; R114-98, 9-8-98)

NAC 453.280 Modification of registration. (NRS 453.221, 453.226, 639.070)

1. Any registrant may apply to have his or her registration modified to allow the handling of additional controlled substances. The application must be in the form of a letter of request and be submitted to the Secretary of the Board. The letter must contain the registrant’s name, address, registration number and the substances or schedules to be added to his or her registration. The letter must be signed by the same person who signed the registrant’s most recent application for registration or reregistration. If the registrant is seeking to handle additional controlled substances listed in schedule I for the purpose of research or instructional activities, the registrant must attach one copy of a federally approved research protocol describing each research project involving the additional substances, or attach two copies of any statement which is filed in support of his or her application for federal registration and describes the nature, extent and duration of those instructional activities, as appropriate. The request for modification will be handled in the same manner as an application for registration.

2. A registration or any authority conferred thereby must not be assigned or otherwise transferred except upon such conditions as the Board may specifically designate and only pursuant to its written consent.

3. The registration of any person automatically terminates if the person dies, ceases legal existence, discontinues business or professional practice, or the person’s name or address is changed from that shown on the certificate of registration. Any registrant who ceases legal existence, discontinues business or professional practice, or whose name or address is changed from that shown on the certificate of registration must notify the Secretary of the Board promptly of that fact. If a change in the name or address of a registrant is to occur, the registrant must apply for a modification of his or her registration before the effective date of the change by filing an application with the Secretary of the Board.

4. A registrant is not required to pay a fee to modify his or her registration pursuant to this section.

[Bd. of Pharmacy, § 453.210, eff. 6-26-80]—(NAC A 11-9-95; 11-14-97)

NAC 453.285 Placement of registration on inactive status: Grounds; effect; duration; notice; reinstatement; appeal. (NRS 453.221, 453.226, 639.070)

1. The Executive Secretary of the Board shall, without a hearing, place the registration of a practitioner on inactive status if:

(a) The Board is notified by an occupational licensing board that a license of the practitioner issued by the occupational licensing board has been placed on inactive status; and

(b) The license that was placed on inactive status is the license in connection with which the practitioner was issued a certificate of registration.

2. A practitioner may not dispense any controlled substance within this State during the period that his or her registration is on inactive status.

3. A registration that is placed on inactive status pursuant to subsection 1 will remain inactive until such time as the registrant presents proof to the Executive Secretary of the Board that the occupational licensing board that licenses the practitioner has reinstated the practitioner’s license to active status.

4. If a registration is placed on inactive status pursuant to subsection 1, the Board will provide written notice to the registrant as soon as practicable after the registration is placed on inactive status. The notice shall inform the registrant that:

(a) The registrant may petition the Executive Secretary of the Board at any time for reinstatement of the registration to active status;

(b) The registrant’s Internet access to the database of the program established pursuant to NRS 453.162 is suspended while the registration remains on inactive status; and

(c) The registrant may request a hearing before the Board to contest the placement of the registration on inactive status.

5. A registrant whose registration is placed on inactive status pursuant to subsection 1 may petition the Executive Secretary of the Board at any time for reinstatement of the registration to active status.

6. If the Executive Secretary of the Board denies a petition for reinstatement of the registration to active status, the Board will provide written notice to the registrant as soon as practicable after the denial of the petition. The notice shall inform the registrant that he or she may request a hearing before the Board to appeal the denial of the petition.

7. To request a hearing before the Board to contest the placement of a registration on inactive status or appeal the denial of a petition for reinstatement of the registration to active status, the registrant must submit a written request for a hearing to the Board not later than 30 days after the date of issuance of the notice pursuant to subsection 4 or 6.

8. If a registrant requests a hearing before the Board pursuant to subsection 7, the Board will conduct a hearing at the next regularly scheduled meeting of the Board, but in any event, the hearing must be instituted and determined within 45 days after the date of the request for a hearing, unless a continuance is requested by the registrant.

(Added to NAC by Bd. of Pharmacy by R071-19, eff. 2-7-2020)

NAC 453.290 Suspension or revocation of registration. (NRS 453.221, 639.070)

1. Upon service of an order suspending or revoking a registration, the registrant shall forthwith deliver his or her certificate of registration, together with all controlled substances in his or her possession, to the Board or its authorized agents.

2. If the revocation or suspension is limited to particular controlled substances, the registrant will be given a new certificate of registration for all substances not affected by the order. A fee is not required for issuance of the new certificate. The registrant shall deliver his or her old certificate, together with all controlled substances in the registrant’s possession which are affected by the order, to the Board or its agent.

[Bd. of Pharmacy, § 453.200, eff. 6-26-80]

NAC 453.300 Inspections of premises. (NRS 453.221, 453.226, 639.070) The Board may inspect, or cause to be inspected, the premises of an applicant or registrant, and in conducting the inspection will review the application for registration and other information regarding the applicant in order to determine whether he or she has met the applicable standards of NRS 453.231.

[Bd. of Pharmacy, § 453.180, eff. 6-26-80]

CONTROL

NAC 453.400 Security of controlled substances. (NRS 453.221, 639.070) All applicants and registrants shall establish and maintain effective controls and procedures to prevent or guard against theft and misuse of controlled substances.

[Bd. of Pharmacy, part § 453.220, eff. 6-26-80]

NAC 453.410 Dispensing of controlled substances by practitioner. (NRS 453.221, 453.246, 639.070)

1. A practitioner, as defined in subsections 1 and 2 of NRS 453.126, who is registered with the Board to possess and dispense controlled substances and dispenses the substances for use by the practitioner’s patients outside his or her presence, shall:

(a) Keep complete, accurate and readily retrievable records of all controlled substances so dispensed. Each written prescription must be serially numbered and kept in numerical order.

(b) Ensure that each record of a controlled substance which is dispensed contains the:

(1) Name of the patient and, if not readily available from the practitioner’s records, the patient’s address.

(2) Name, strength and quantity of the controlled substance dispensed.

(3) Date the controlled substance was dispensed.

(4) Name of the prescribing practitioner and the classification of his or her license.

(5) Practitioner’s registration number issued by the Drug Enforcement Administration of the United States Department of Justice.

(6) Initials of the dispensing practitioner, if the dispensing practitioner did not prescribe the controlled substance.

(7) Directions for use.

(8) Signature of the prescribing practitioner.

Ê The practitioner shall provide this information to an agent of the Board upon request.

(c) Maintain a separate file for the records concerning the purchase of each controlled substance listed in schedule II and a separate file for the records concerning the dispensing of each controlled substance listed in schedule II. Each prescription for a controlled substance or dangerous drug must be maintained in a separate file pursuant to the requirements set forth in NAC 453.480.

(d) Keep all controlled substances and dangerous drugs in a locked storage area. Access to the storage area must be restricted to the persons described in NRS 453.375.

(e) Ensure that each package or container in which a controlled substance is dispensed, except samples in the manufacturer’s packages, is clearly labeled pursuant to the requirements set forth in NRS 639.2801.

(f) Ensure that the package or container in which a controlled substance or dangerous drug is dispensed complies with all state and federal packaging requirements.

2. A practitioner may dispense dangerous drugs or controlled substances to a patient only after he or she has issued a written prescription that authorizes the patient to have it filled at another location of the patient’s choosing or by the dispensing practitioner.

[Bd. of Pharmacy, § 453.230, eff. 6-26-80]—(NAC A 9-29-87; 8-31-88; 2-6-90; 8-27-96)

NAC 453.420 Dispensing of schedule II controlled substance in emergency. (NRS 453.221, 453.256, 453.385, 639.070)

1. In an emergency situation, a pharmacist may dispense a controlled substance listed in schedule II upon receiving the oral authorization of a prescribing individual practitioner, if:

(a) The quantity prescribed and dispensed is limited to the amount adequate to treat the patient during the emergency period. Any dispensing beyond the emergency period must be pursuant to a written prescription signed by the prescribing practitioner.

(b) The pharmacist immediately reduces the prescription to writing and:

(1) The prescription contains all information required pursuant to NAC 453.440, except for the signature of the prescribing practitioner;

(2) He or she writes on its face “Authorization for Emergency Dispensing” and the date of the oral order; and

(3) He or she makes a reasonable effort to determine that the oral authorization came from a registered practitioner when the practitioner is not personally known to the pharmacist, which may include, without limitation, a telephone call to the telephone number of the practitioner as listed in the telephone directory or other attempts in good faith to verify the identity of the practitioner.

2. The prescribing practitioner, within 72 hours after authorizing an emergency oral prescription, shall cause a written prescription for the emergency quantity prescribed to be delivered to the dispensing pharmacist. The written prescription may be delivered to the pharmacist in person or by mail. If the written prescription is delivered by mail, it must be postmarked within the 72-hour period. Upon receipt, the dispensing pharmacist shall attach this prescription to the oral emergency prescription which had earlier been reduced to writing.

3. The pharmacist shall notify the Board if the prescribing practitioner fails to deliver a written prescription to him or her pursuant to this section. The failure of the pharmacist to so notify the Board voids his or her authority to dispense a controlled substance listed in schedule II without a written prescription of a prescribing practitioner pursuant to this section.

[Bd. of Pharmacy, § 453.270, eff. 6-26-80]—(NAC A by R020-98, 4-17-98; R111-99, 11-3-99)

NAC 453.430 Restrictions on issuance of prescriptions; continuation of dependency on narcotic drug authorized under certain circumstances. (NRS 453.221, 453.385, 639.070, 639.23535)

1. An individual practitioner may not issue a prescription in order to obtain controlled substances for the purpose of general dispensing to patients.

2. A prescription may not be issued for dispensing any narcotic drug to a person dependent on a narcotic drug for the purpose of continuing the person’s dependence upon the drug except in the course of an authorized clinical investigation in the development of a program for rehabilitating persons with a narcotic use disorder.

3. The administering or dispensing directly, but not the prescribing, of any narcotic drugs to a person dependent on a narcotic drug for the purpose of continuing the person’s dependence upon the drug is permissible in the course of conducting a federally authorized clinical investigation in the development of a program for rehabilitating persons with a narcotic use disorder if the activity is within the course of professional practice or research.

[Bd. of Pharmacy, § 453.240, eff. 6-26-80]—(NAC A by R164-01, 12-17-2001; R083-20, 12-29-2020, eff. 1-1-2021)

NAC 453.440 Prescriptions: Contents; additions and changes. (NRS 453.221, 453.385, 639.070)

1. Except as otherwise provided in subsection 3, each prescription for a controlled substance must contain:

(a) The name of the prescribing practitioner;

(b) The address of the prescribing practitioner if not immediately available to the pharmacist or pharmaceutical technician;

(d) The full name and date of birth of the patient;

(e) The address of the patient if not immediately available to the pharmacist or pharmaceutical technician;

(f) The name, strength and quantity of the drug or drugs prescribed;

(g) The directions for use;

(h) The days’ supply of the controlled substance;

(i) The ICD-10 code that corresponds to the diagnosis for which the controlled substance is prescribed;

(j) The classification of the license of the prescribing practitioner; and

(k) The registration number from the Drug Enforcement Administration of the prescribing practitioner. If the prescription is written on a preprinted form that lists the names and registration numbers of more than one practitioner, the name and registration number of the prescribing practitioner must be clearly indicated by a mark.

2. Each written prescription for a controlled substance must include, in addition to the information required by subsection 1, the handwritten signature of the prescribing practitioner in nonerasable ink.

3. A prescription issued by a person who is authorized to prescribe controlled substances in the course of his or her official duties and who is exempted from registration pursuant to 21 C.F.R. § 1301.23 may be filled if, in lieu of the requirements set forth in paragraphs (a) and (k) of subsection 1, it contains:

(a) The name of the person who issued the prescription stamped or printed on it;

(b) The branch of military service or the agency pursuant to which the person who issued the prescription is authorized to prescribe controlled substances in the course of his or her official duties; and

(c) The service identification number of the person who issued the prescription. Pursuant to 21 C.F.R. § 1301.23, the service identification number for an employee of the United States Public Health Service is his or her social security number.

4. Except as otherwise provided in this subsection and subsection 3, if the address of the prescribing practitioner or the address of the patient is not on the prescription, before filling the prescription, the pharmacist or pharmaceutical technician shall write the missing address or addresses on the prescription or shall record the missing address or addresses in the record of the prescription in the computer system used by the pharmacy. If the address or addresses are immediately available to the pharmacist or pharmaceutical technician by an alphabetical card file, computer, patient profile system or any other system approved by the Board, the pharmacist or pharmaceutical technician need not write the address or addresses on the prescription or record the address or addresses in the record of the prescription in the computer system used by the pharmacy but shall place on the prescription or in the record of the prescription his or her initials and a notation indicating the addresses are immediately available, including, without limitation, “RA,” “readily available,” “in files,” “on computer” or any other similar notation.

5. Except as otherwise provided in subsection 3, if the address of the prescribing practitioner or the address of the patient is not on the prescription and the address of the prescribing practitioner or the address of the patient are not immediately available to the pharmacist or pharmaceutical technician, or if the address or addresses have been added by the patient or a person other than the practitioner, before dispensing the prescription an employee of the pharmacy shall:

(a) If the address of the patient is missing or added, obtain:

(1) Positive identification from the patient to verify his or her identity and address; or

(2) Verification from the practitioner or his or her agent of the identity and address of the patient.

(b) If the address of the practitioner is missing or added, obtain verification from the practitioner or his or her agent of the address of the practitioner.

Ê An employee of the pharmacy shall place his or her initials and a notation indicating the person who provided the identification or verification to the pharmacist or pharmaceutical technician on the prescription or in the record of the prescription in the computer system used by the pharmacy.

6. A pharmacist or pharmaceutical technician shall not add or change the registration number issued to a practitioner by the Drug Enforcement Administration on a prescription for a controlled substance.

7. A pharmacist:

(a) May, after obtaining approval of the practitioner who issued the prescription, add or change the following information on a prescription for a controlled substance listed in schedule II:

(1) The strength of the drug prescribed;

(2) The quantity of the drug prescribed;

(3) The directions for use;

(4) The date that the prescription was issued;

(5) The days’ supply of the drug prescribed;

(6) The ICD-10 code that corresponds to the diagnosis for which the drug is prescribed; and

(7) The date of birth of the patient.

(b) May not add or change the following information on a prescription for a controlled substance listed in schedule II:

(1) The name of the patient;

(2) The name of the controlled substance prescribed except that the pharmacist may change the name of the controlled substance to reflect the generic name of the controlled substance if the pharmacist substituted a generic controlled substance for the controlled substance prescribed; or

(3) On a written prescription, the signature of the prescribing practitioner.

(1) Initial any addition or change made pursuant to paragraph (a) on the prescription or in the record of the prescription in the computer system used by the pharmacy; and

(2) Make a notation on the prescription or in the record of the prescription in the computer system used by the pharmacy of:

(I) The date and time that the prescribing practitioner approved the addition or change; and

(II) The reason for the addition or change.

8. For the purposes of this section:

(a) “Days’ supply” means the fewest number of days necessary to consume the quantity of the controlled substance dispensed to the patient if the patient consumes the maximum dose of the controlled substance authorized by the prescribing practitioner.

(b) “ICD-10 code” means the code established in the International Classification of Diseases, Tenth Revision, Clinical Modification, adopted by the National Center for Health Statistics and the Centers for Medicare and Medicaid Services or the code used in any successor classification system adopted by the National Center for Health Statistics and the Centers for Medicare and Medicaid Services.

[Bd. of Pharmacy, § 453.250, eff. 6-26-80]—(NAC A 6-25-82; 2-6-90; 10-1-93; 1-10-94; R164-01, 12-17-2001; R042-07, 12-4-2007; R050-07, 12-17-2008; R046-17, 2-27-2018)

NAC 453.450 Prescriptions for schedule II controlled substances. (NRS 453.146, 453.221, 453.385, 639.070)

1. A pharmacist may dispense a controlled substance listed in schedule II only pursuant to:

(a) A written prescription, including a written prescription described in subsection 1 of NAC 639.711 that is transmitted by a practitioner or his or her agent by a facsimile machine to a pharmacy; or

(b) An emergency oral prescription authorized by a prescribing practitioner pursuant to NAC 453.420.

2. Except as otherwise provided in subsection 4, a prescription blank may contain more than one controlled substance listed in schedule II. Except as otherwise provided in subsection 4, a prescription blank that contains a controlled substance listed in schedule II may include other controlled substances not listed in schedule II and other prescription drugs. If a prescription for a controlled substance listed in schedule II is written on the same prescription blank with a prescription for another drug, including another controlled substance listed in schedule II, the pharmacy or dispensing practitioner shall maintain the original prescription blank in the file maintained pursuant to NAC 453.480 for controlled substances listed in schedule II. After the prescription for the controlled substance listed in schedule II is filled, the pharmacy or dispensing practitioner shall make a copy of the prescription blank for each of the other prescriptions written on that prescription blank and file the copy of the prescription blank in the appropriate file maintained pursuant to NAC 453.480. Each copy of the prescription blank filed must include:

(a) A reference to the serial number of the prescription for a controlled substance listed in schedule II; or

(b) If the prescription blank contains more than one controlled substance listed in schedule II, a reference to the serial number of the first prescription for a controlled substance listed in schedule II.

3. Except as otherwise provided in this subsection, a pharmacist shall return, upon request by a patient or a patient’s agent or representative, any written prescription for a controlled substance listed in schedule II. If the pharmacist verifies that the prescription has previously been filled and dispensed to the patient, the pharmacist shall not return the prescription to the patient or the patient’s agent or representative.

4. A practitioner who wishes to issue a prescription for a controlled substance listed in schedule II on which it is indicated that the prescription may not be filled until a future date must use the phrase “Do not fill before (date)” or “Do not dispense until (date)” or other similar words on the prescription to indicate that the prescription may not be filled before the date indicated. The date indicated by the practitioner must not be later than 3 months after the date on which the prescription is written. The date indicated by the practitioner is the date of issue for the purposes of subsection 4 of NRS 453.431. No combination of prescriptions issued pursuant to this subsection may exceed a 90-day supply based on the date indicated for the earlier of the prescriptions. Any prescription issued pursuant to this subsection must not be included on a prescription blank or other document prescribing any other dangerous drug or controlled substance.

[Bd. of Pharmacy, § 453.260, eff. 6-26-80]—(NAC A by R164-01, 12-17-2001; R039-04, 5-25-2004; R035-07 & R042-07, 12-4-2007; R049-08, 6-17-2008)

NAC 453.460 Partial filling of prescription. (NRS 453.221, 453.385, 639.070)

1. A pharmacist may partially fill a prescription for a controlled substance listed in schedule II:

(a) If the partial filling is requested by a patient or the prescribing practitioner and the total quantity of the controlled substance that is dispensed in all partial fillings does not exceed the total quantity of the controlled substance that is prescribed. Except as otherwise provided in this paragraph, the remaining portion of the prescription may be filled, but in any event must not be filled more than 30 days after the date on which the prescription was written. In an emergency situation as set forth in 21 U.S.C. § 829(a), the remaining portion of the prescription must be filled not later than 72 hours after the prescription was issued.

(b) For a patient in a facility for long-term care or for a patient who has been diagnosed as having a terminal illness. The pharmacist shall record on the prescription that the patient is a “LTC patient” or “terminally ill.” The date of the partial filling, the quantity of the medication that is dispensed, the remaining quantity which is authorized to be dispensed, and the signature or initials of the pharmacist must be recorded on the back of the prescription. The total quantity of the controlled substance that is dispensed in all partial fillings must not exceed the total quantity of the controlled substance that is prescribed. A prescription is valid for 60 days after the date of the prescription unless the prescription is terminated earlier by the discontinuance of medication.

2. A pharmacist may partially fill a prescription for a controlled substance listed in schedule III, IV or V. A partial filling of a prescription pursuant to this subsection does not constitute a refill for the purposes of subsection 3 of NRS 453.256. A prescription that is partially filled pursuant to this subsection is not completely filled until the total quantity dispensed in all partial fillings equals the total quantity prescribed.

3. Whenever a patient requests a partial filling, a pharmacist shall:

(a) Create and maintain a record of each partial filling that reflects the total quantity dispensed for any particular prescription;

(b) Ensure that the total quantity dispensed in all partial fillings does not exceed the total quantity prescribed; and

(1) Schedule II more than 30 days after the date on which the prescription was written; and

(2) Schedule III, IV or V more than 6 months after the date on which the prescription was issued.

4. As used in this section, “facility for long-term care” means a medical facility that provides 24-hour nursing services.

[Bd. of Pharmacy, § 453.280, eff. 6-26-80]—(NAC A 3-17-92; R021-98, 4-17-98; R019-01, 11-1-2001; R049-07, 1-30-2008; R007-17, 2-27-2018)

NAC 453.470 Information to be affixed to package for prescription. (NRS 453.221, 639.070) A person authorized by the Board to dispense controlled substances who fills a written prescription for a controlled substance listed in schedule II, III or IV, or an emergency oral prescription for a controlled substance listed in schedule II, shall affix to the package a label showing:

1. The name and address of the pharmacy;

2. The serial number and date of initial filling of the prescription;

3. The name of the patient;

4. The name of the prescribing practitioner; and

5. Any directions for use and cautionary statements contained in the prescription or required by law.

[Bd. of Pharmacy, § 453.290, eff. 6-26-80]—(NAC A 1-10-94)

NAC 453.475 Initial and biennial inventory of controlled substances by new managing pharmacist. (NRS 453.221, 453.246, 639.070)

1. A pharmacist who is hired or promoted to manage a pharmacy pursuant to the provisions of NRS 639.220 shall:

(a) Within 48 hours after first reporting for duty as the managing pharmacist, conduct an inventory of the controlled substances of the pharmacy with the pharmacist who preceded him or her as the managing pharmacist. The pharmacists shall sign the inventory.

(b) After the date on which the inventory required pursuant to paragraph (a) was taken, conduct an inventory of the controlled substances of the pharmacy at least once every 2 years during the course of his or her employment as managing pharmacist at the pharmacy. The managing pharmacist may conduct the biennial inventory on any date which is within 2 years of the date on which the previous biennial inventory was conducted.

2. An inventory required by subsection 1 must be:

(a) Conducted according to the method prescribed by the provisions of 21 C.F.R. Part 1304; and

(b) Placed in the records of the controlled substances of the pharmacy.

(Added to NAC by Bd. of Pharmacy, eff. 8-10-89; A 7-7-94; R022-98, 4-17-98; R015-01, 11-1-2001)

NAC 453.480 Maintenance of files of prescriptions. (NRS 453.221, 453.246, 639.070) In maintaining files of prescriptions, a pharmacy or dispensing practitioner must elect one of the following options:

1. To maintain two files:

(a) One file for substances in schedule II; and

(b) The other file for substances in schedules III, IV and V and for noncontrolled substances if the prescriptions for controlled substances are:

(1) Stamped in the lower right-hand corner with the letter “C” in red ink at least 1 inch in height; or

(2) Not stamped because the pharmacy uses a computerized system to record information concerning prescriptions that meets the requirements of 21 C.F.R. § 1304.04(h)(2).

2. To maintain two files:

(a) One file for substances in schedules II, III, IV and V if the prescriptions for substances in schedules III, IV and V are stamped with the red letter “C” or not stamped as set forth in paragraph (b) of subsection 1; and

(b) The other file for prescriptions for noncontrolled substances.

3. To maintain three files:

(a) One file for substances in schedule II;

(b) A second file for substances in schedules III, IV and V; and

[Bd. of Pharmacy, § 453.300, eff. 6-26-80]—(NAC A by R023-98, 4-17-98)

NAC 453.485 Records to be maintained by pharmacist. (NRS 453.221, 453.246, 639.070)

1. A pharmacist shall maintain the following records in connection with any sale of supplies of controlled substances to a practitioner:

(a) The form numbered 222 of the Drug Enforcement Administration or the order, if the drug is a schedule III, IV or V controlled substance, presented in connection with the purchase. The form or order must contain the following information:

(1) The name of the practitioner, and his or her address if it is not immediately available to the pharmacist.

(2) The classification of the practitioner’s license.

(3) The name, strength and quantity of the drug supplied.

(4) The date of issue.

(b) A certification, which may be placed on the written order or on a separate paper attached to the written order, signed by the pharmacist filling the order and the person receiving the order and specifying:

(1) The date the order was filled by the pharmacy; and

(2) Any deletion or change in the order.

2. A pharmacist shall maintain the following records in connection with any sale or replenishment of supplies of controlled substances to the holder of a permit for the operation of an ambulance, air ambulance or a vehicle of a fire-fighting agency at the scene of an emergency:

(a) The purchase order, which must contain the following information:

(1) The name of the patient.

(2) The date of the order.

(3) The name, strength and quantity of the drug.

(4) The number of the run of the specific vehicle, which references the record of transport or treatment of the patient.

(b) A certification, which may be placed on the purchase order or on a separate paper attached to the purchase order, signed by the pharmacist filling the order and the person receiving the order and specifying:

(1) The date the order was filled by the pharmacy;

(2) Any deletion or change in the controlled substances furnished pursuant to the order; and

(3) The number of the certificate or license of the practitioner, intermediate emergency medical technician, advanced emergency medical technician-ambulance or registered nurse in charge of the controlled substances on the ambulance, air ambulance or vehicle of a fire-fighting agency, if the number is not on file in the pharmacy.

(Added to NAC by Bd. of Pharmacy, eff. 10-17-86)

NAC 453.488 Lost or stolen order forms. (NRS 453.221, 453.246, 639.070) If an order form of the Drug Enforcement Administration (DEA 222) has been lost by or stolen from a pharmacy, a pharmacist employed by the pharmacy shall immediately upon discovery of the loss or theft report the loss or theft to the Office of Diversion Control, Drug Enforcement Administration, Los Angeles Field Division, 255 East Temple Street, 20th Floor, Los Angeles, California 90012, (888) 415-9822, in accordance with the provisions of 21 C.F.R. § 1305.12(b).

(Added to NAC by Bd. of Pharmacy by R029-98, eff. 4-17-98)

NAC 453.490 Dispensing of controlled substances which are not prescription drugs. (NRS 453.221, 453.246, 639.070)

1. Except as otherwise provided in subsection 3, a controlled substance listed in schedule V, and a controlled substance listed in schedule II, III or IV which is not a prescription drug as determined under the Federal Food, Drug and Cosmetic Act, may be dispensed by a pharmacist without a prescription to a purchaser at retail, if:

(a) The dispensing is only by a pharmacist;

(b) Not more than 60 cc (or 2 ounces) of the controlled substance is distributed to the same purchaser in any 48-hour period;

(d) The pharmacist requires the purchaser who is not known to him or her to furnish suitable identification, including proof of age where appropriate;

(e) The pharmacist maintains a bound book to record the dispensing of controlled substances other than by prescription, and the book contains:

(1) The name and address of the purchaser;

(2) The name and quantity of controlled substance purchased;

(3) The date of each purchase; and

(4) The name or initials of the pharmacist who dispensed the substance to the purchaser; and

(f) A prescription for dispensing or the distribution of the substance is not required by any federal, state or local law.

2. Paregoric may be dispensed for treatment of the stomach or bowel if:

(a) It has been mixed with 3 ounces or more of a nonnarcotic medicinal preparation or combination of nonnarcotic medicinal preparations; and

(b) The resulting mixture contains not more than 1 ounce of paregoric.

3. A cough syrup containing a controlled substance listed in schedule V may only be dispensed for a valid and legitimate medical purpose, and the dispensing pharmacist shall ensure that a valid and legitimate medical purpose exists in every instance of such dispensing.

[Bd. of Pharmacy, § 453.310, eff. 6-26-80]—(NAC A 10-17-86)

SCHEDULES OF CONTROLLED SUBSTANCES

NAC 453.510 Schedule I. (NRS 453.146, 453.2182, 639.070)

1. Schedule I consists of the drugs and other substances listed in this section by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including, without limitation, their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:

Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

Acetylmethadol;

Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (some trade or other names: acryloylfentanyl);

Allylprodine;

Alphacetylmethadol (except levo-alphacetylmethadol, commonly referred to as levo-alpha-acetylmethadol, levomethadyl acetate or “LAAM”);

Alphameprodine;

Alphamethadol;

Alphamethylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

Benzethidine;

Betacetylmethadol;

Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);

Beta-hydroxythiofentanyl (trade or other names: N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide; N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide);

Betameprodine;

Betamethadol;

Betaprodine;

Butyryl fentanyl (trade or other names: N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide; N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);

Clonitazene;

Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

Dextromoramide;

Diampromide;

Diethylthiambutene;

Difenoxin;

Dimenoxadol;

Dimepheptanol;

Dimethylthiambutene;

Dioxaphetyl butyrate;

Dipipanone;

Ethylmethylthiambutene;

Etonitazene;

Etoxeridine;

Eutylone (bk-EBDB, 1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)butan-1-one, b-keto-ethylbenzodioxolylbutanamine);

Fentanyl carbamate (Ethyl-(1-phenethylpiperidin-4-yl)(phenyl)carbamate);

Fluoro furanyl fentanyl;

Fluoroacryl fentanyl;

Fluorobutyryl fentanyl;

Fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide);

Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

Furethidine;

Hydroxypethidine;

Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

Isotonitazene;

Ketobemidone;

Levomoramide;

Levophenacylmorphan;

Methoxyacetyl fentanyl;

Methyl acetyl fentanyl;

Methyl methoxyacetyl fentanyl (some trade or other names: 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl));

Methylfentanyl;

Methylthiofentanyl;

Morpheridine;

MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

Noracymethadol;

Norlevorphanol;

Normethadone;

N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2’-fluoro ortho-fluorofentanyl; 2’-fluro 2’-fluorofentanyl);

Norpipanone;

Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide;

Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);

Phenadoxone;

Phenampromide;

Phenomorphan;

Phenoperidine;

Phenyl fentanyl (some trade or other names: benzoyl fentanyl);

Phenylpropanoyl fentanyl;

Piritramide;

Proheptazine;

Properidine;

Propiram;

Racemoramide;

Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);

Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);

Thiofuranyl fentanyl (some trade or other names: thiophene fentanyl);

Tilidine;

Trimeperidine; or

Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide).

3. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, including, without limitation, their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

Acetorphine;

Acetyl fentanyl;

Acetyldihydrocodeine;

Benzylmorphine;

Codeine methylbromide;

Codeine-N-Oxide;

Cyprenorphine;

Desomorphine;

Dihydromorphine;

Drotebanol;

Etorphine (except hydrochloride salt);

Heroin;

Hydromorphinol;

Methyldesorphine;

Methyldihydromorphine;

Morphine methylbromide;

Morphine methylsulfonate;

Morphine-N-Oxide;

Myrophine;

Nicocodeine;

Nicomorphine;

Normorphine;

Pholcodine; or

Thebacon.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, including, without limitation, their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

Adinazolam (some trade or other names: 8-chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; adinazolamum; Deracyn);

Alpha-ethyltryptamine (some trade or other names: ET, Trip);

Alpha-methyltryptamine (some trade or other names: AMT);

Bromazolam (some trade or other names: 8-bromo-1-methyl-6-phenyl-4H[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; XLI-268);

1,4-Butanediol (some trade or other names: 1,4-butyleneglycol, dihydroxybutane, tetramethylene glycol, butane 1,4-diol, SomatoPro, Soma Solutions, Zen);

4-bromo-2,5-dimethoxyamphetamine (some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA);

4-bromo-2,5-dimethoxyphenethylamine (some trade or other names: Nexus, 2C-B);

1-Butyl-3-(1-naphthoyl)indole-7173 (some trade or other names: JWH-073);

2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (some trade or other names: 2C-C);

4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (some trade or other names: Etizolam);

Clonazolam (some trade or other names: 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; clonitrazolam);

1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (some trade or other names: SR-18; BTM-8; RCS-8);

Diclazepam (some trade or other names: 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one; 2’-chlorodiazepam; Chlorodiazepam; Ro 5-3448);

2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

2,5-dimethoxy-4-ethylamphet-amine (some trade or other names: DOET);

2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (some trade or other names: 2C-E);

2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (some trade or other names: 2C-D);

2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (some trade or other names: 2C-N);

2,5-Dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) and any derivative thereof (some trade or other names: 2C-X-NBOMe; N-benzylated phenethylamines; N-o-methoxybenzyl analogs; NBOMe; 25H-NBOMe; 25B-NBOMe; 25C-NBOMe; 25D-NBOMe; 25E-NBOMe; 25I-NBOMe; 25N-NBOMe; 25P-NBOMe; 25T2-NBOMe; 25T4-NBOMe; 25T7-NBOMe);

2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (some trade or other names: 2C-P);

2,5-dimethoxy-4-(n)-propylthiophenethylamine (some trade or other names: 2C-T-7);

2-(2,5-Dimethoxyphenyl)ethanamine (some trade or other names: 2C-H);

3-[(2-Dimethylamino)ethyl]-1H-indol-4-yl acetate (some trade or other names: 4-acetoxy-N, N-dimethyltryptamine;4-AcO-DMT; psilacetin; O-acetylpsilocin; 4-acetoxy-DMT);

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol-7297 (some trade or other names: CP-47,497);

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol-7298 (some trade or other names: cannabicyclohexanol; CP-47,497 C8 homologue);

Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (some trade or other names: 5F-EDMB-PINACA);

4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (some trade or other names: (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone; JWH-210);

2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (some trade or other names: 2C-T-2);

Flualprazolam (some trade or other names: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-(2-fluoro-phenyl)-1-methyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine; 2’-fluoro alprazolam; ortho-fluoro alprazolam);

Flubromazepam (some trade or other names: 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Bromo-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one; 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one);

Flubromazolam (some trade or other names: 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine);

Flunitrazolam (some trade or other names: 6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine);

(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: FUB-144);

2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (Some trade or other names: FUB-AMB; MMB-FUBINACA);

[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (some trade or other names: THJ-2201; 5-fluoro THJ 018; AM2201 indazole analog; fluorpentyl JWH-018 indazole);

[1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone (some trade or other names: 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; AM-2201);

[1-(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophyenyl)-methanone (some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; AM-694);

(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: XLR-11);

1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (some trade or other names: 5F-CUMYL-PINACA; SGT-25);

1-(5-fluoropentyl)-N-(tricyclo[3.3.1.13,7]dec-1-yl)-1H-indazole-3-carboxamide (some trade or other names: N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; APINACA 5-fluoropentyl analog; 5F-AKB48; 5-Fluoro-AKB48; 5F-APINACA; 5-Fluoro-APINACA;

1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (some trade or other names: 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester; 5-Fluoro-PB-22; 5F-PB-22);

Flutoprazepam (some trade or other names: 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (some trade or other names: 2C-I);

2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (some trade or other names: 2C-T-4);

1-hexyl-3-(1-naphthoyl)indole (some trade or other names: JWH-019);

Meclonazepam (some trade or other names: (3S)-5-(2-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2H-1,4-benzodiazepin-2-one; Ro 11-3128);

Methoxetamine (some trade or other names: MXE; 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone)

4-methoxyamphetamine (some trade or other names: 4-methoxy-alpha-methylphenethylamine; para-methoxyamphetamine; PMA);

(4-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone (some trade or other names: JWH-081);

5-methoxy-3,4-methylenedioxyamphetamine (some trade or other names: MMDA);

5-methoxy-N, N-diisopropyltryptamine (some trade or other names: 5-meO-DIPT);

4-methyl-2,5-dimethoxyamphetamine (some trade or other names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; “DOM”; “STP”);

(4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone (some trade or other names: JWH-122);

Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (some trade or other names: 5F-ADB; 5F-MDMB-PINACA);

Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (some trade or other names: 5F-MDMB-PICA);

Methylenedioxyamphetamine (some trade or other names: MDA);

Methylenedioxymethamphetamine (MDMA);

Methylenedioxy-N-ethylamphetamine (commonly referred to as N-ethyl-alpha-methyl-3,4(methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole-7200 (some trade or other names: JWH-200);

N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (some trade or other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-fluorobenzyl);

N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide; APINACA; AKB48);

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (trade or other names: ADB-CHMINACA; MAB-CHMINACA);

N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (trade or other name: ADB-PINACA);

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: AB-PINACA);

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (trade or other name: AB-FUBINACA);

N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (trade or other name: AB-CHMINACA);

N-hydroxy-3,4-methylenedioxyamphetamine (commonly referred to as N-hydroxy-alpha-methyl-3,4(methylenedioxy) phenethylamine, N-hydroxy MDA);

2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (some trade or other names: 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone; 1-pentyl-3-(2-methoxyphenylacetyl)indole; JWH-250);

Nifoxipam (some trade or other names: 5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-5-(2-fluorophenyl)-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-one; 3-hydroxydesmethylflunitrazepam; DP 370);

Nitrazolam (some trade or other names: 1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

Norflurazepam (some trade or other names: 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; nor-Flurazepam; N-Desalkylflurazepam; Desalkylflurazepam; Ro 5-3367);

1-Pentyl-3-(2-chlorophenylacetyl)indole (some trade or other names: JWH-203);

1-Pentyl-3-(4-cholor-1-naphthoyl)indole (some trade or other names: JWH-398);

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (some trade or other names: SR-19; BTM-4; RCS-4);

1-Pentyl-3-(1-naphthoyl)indole-7118 (some trade or other names: JWH-018; AM678);

(1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (some trade or other names: UR-144);

1-pentyl-N-(tricyclo[3.3.1.1^3,7]dec-1-yl-1H-indole-3 carboxamide (some trade or other names: APICA; JWH-018 adamantyl carboxamide; 2NE1; SDB-001);

1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (some trade or other names: 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester; PB-22; QUPIC);

Phenazepam (some trade or other names: 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-bromo-5-(2-chlorophenyl)-1,2-dihydro-3H-1,4-benzodiazepin-2-one; BD 98; Fenazepam; Elzepam; Phezipam; Phenorelaxan; Phenzitat);

Pyrazolam (some trade or other names: 8-bromo-1-methyl-6-(2-pyridinyl)-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; 8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine; Pirazolam);

3,4,5-trimethoxyamphetamine;

Bufotenine (some trade or other names: 3-(beta-dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethyl-aminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N, N-dimethyltryptamine; mappine);

Diethyltryptamine (some trade or other names: DET; N,N-Diethyltryptamine);

Dimethyltryptamine (some trade or other names: DMT; N,N-DMT; N,N-Dimethyltryptamine);

Fluorophenylpiperazine (some trade or other names: FPP, pFPP, 2-fluorophenylpiperazine, 3-fluorophenylpiperazine, 4-fluorophenylpiperazine);

Gamma butyrolactone (some trade or other names: GBL, Gamma Buty Lactone, 4-butyrolactone, dihydro-2(3H)-furanone, tetrahydro-2-furanone, Gamma G, GH Gold);

Gamma hydroxy butyric acid (some trade or other names: GHB);

Ibogaine (some trade or other names: 7-ethyl-6, 6 beta, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1’,2’:1,2) azepino (5,4-b) indole; Tabernanthe iboga);

Lysergic acid diethylamide;

Marijuana;

Mescaline;

Methoxyphenylpiperazine (some trade or other names: MeOPP, pMPP, 4-MPP, 2-MeOPP, 3-MeOPP, 4-MeOPP);

Parahexyl (some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl);

Peyote (meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts);

N-benzylpiperazine (some trade or other names: BZP, 1-benzylpiperazine);

N-ethyl-3-piperidyl benzilate;

N-methyl-3-piperidyl benzilate;

Psilocybin;

Psilocin;

Salvinorin A (some trade or other names: Divinorin A; Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10- dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate);

Ethylamine analog of phencyclidine (some trade or other names: N-ethyl-1-phenylcyclohexylamine; (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl) ethylamine; cyclohexamine; PCE);

Pyrrolidine analog of phencyclidine (some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP);

1-(1-(2-thienyl)-cyclohexyl)-pyrrolidine (some trade or other names: TCPy);

Thiophene analog of phencyclidine (some trade or other names: 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-thienyl analog of phencyclidine; TPCP; TCP); or

Trifluoromethylphenylpiperazine (some trade or other names: 1-(3-trifluoromethylphenyl)piperazine; 3-trifluoromethylphenylpiperazine; TFMPP).

For the purposes of this subsection, “isomer” includes, without limitation, the optical, position or geometric isomer.

5. All parts of the plant presently classified botanically as Datura, whether growing or not, the seeds thereof, any extract from any part of such plant or plants, and every compound, manufacture, salt derivative, mixture or preparation of such plant or plants, its seeds or extracts, unless substances consistent with those found in such plants are present in formulations that the Food and Drug Administration of the United States Department of Health and Human Services has approved for distribution.

6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of phencyclidine, mecloqualone or methaqualone having a depressant effect on the central nervous system, including, without limitation, their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.

7. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including, without limitation, their salts, isomers and salts of isomers:

Alpha-PBP (some trade or other names: 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one, alpha-pyrrolidinobutiophenone);

Alpha-PVP (some trade or other names: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, alpha-pyrrolidinopentiophenone, alpha-pyrrolidinovalerophenone, O-2387);

Alpha-pyrrolidinoheptaphenone (some trade or other names: PV8);

Alpha-pyrrolidinohexanophenone (some trade or other names: alpha-PHP);

Aminorex;

Butylone (some trade or other names: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one, β-keto-N-methylbenzodioxolylpropylamine, bk-MBDB);

Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2-aminopropiophenone; norephedrone);

4-chloro-alpha-pyrrolidinovalerophenone (some trade or other names: 4-chloro-a-PVP);

Dimethylone (some trade or other names: 3,4-methylenedioxy-N,Ndimethylcathinone; N,N-dimethyl MDCATH; N,N-dimethyl-3,4- methylenedioxycathinone; N,N-dimethyl-β-keto-3,4-methylenedioxyamphetamine; 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one; bk-MDDMA);

N-ethylhexedrone;

Ethylone (some trade or other names: N-ethyl-3,4-methylenedioxycathinone; 1-(1,3- benzodioxol-5-yl)-2-(ethylamino)propan-1-one; MDEC; bk-MDEA);

N-ethylpentylone (1-(1,3-benzodioxol-5-yl)-2-ethylamino)-pentan-1-one) (some trade or other names: ephylone);

Fenethylline;

Fluoroamphetamine (some trade or other names: 2-fluoroamphetamine, 3-fluoroamphetamine, 4-fluoroamphetamine, 2-FA, 3-FA, 4-FA, PFA);

Fluoromethcathinone (some trade or other names: 4-Fluoro-N-methylcathinone, 1-(4-fluorophenyl)-2-(methylamino)propan-1-one, 4-Fluoromethcathinone (Flephedrone), 4-FMC, 3-Fluoro-N-methylcathinone, 1-(3-fluorophenyl)-2-2(methylamino)propan-1-one, 3-Fluoromethcathinone, 3-FMC, 2-Fluoro-N-methylcathinone, 1-(2-fluorophenyl)-2-(methylamino)propan-1-one, 2-FMC);

Mephedrone (some trade or other names: Methylmethcathinone, 4-Methylmethcathinone, 4-MMC, 4-Methylephedrone);

Methamphetamine;

Methcathinone (some trade or other names: N-Methylcathinone, cat);

Methedrone (some trade or other names: Methoxymethcathinone, 4-Methoxymethcathinone, bk-PMMA, methoxyphedrine);

4-methyl-alpha-ethylaminopentiophenone (some trade or other names: 4-MEAP);

4’-methyl-alpha-pyrrolidinohexiophenone (some trade or other names: MPHP);

4-methyl-alpha-pyrrolidinopropiophenone (some trade or other names: 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one, 4-MePPP);

(±)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

Methylenedioxypyrovalerone (some trade or other names: 3,4-Methylenedioxypyrovalerone, MDPV);

Methylethcathinone (some trade or other names: 2-(ethylamino)-1-(4-methylphenyl)propan-1-one, 4-MEC, 4-methyl-N-ethylcathinone);

Methylone (some trade or other names: Methylenedioxy-N-methylcathinone, Methylenedioxymethcathinone, 3,4-Methylenedioxy-N-methylcathinone, bk-MDMA);

N,N-dimethylamphetamine (commonly referred to as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine);

N-ethylamphetamine;

Naphyrone (some trade or other names: 1-(naphthalen-2-yl)-2(pyrrolidin-1-yl)pentan-1-one, naphthylpyrovalerone, naphpyrovalerone, NRG-1, O-2482);

Pentedrone (some trade or other names: 2-(methylamino)-1-phenylpentan-1-one, α-methylaminovalerophenone); or

Pentylone (trade or other names: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one; beta-keto-methylbenzodioxolylpentanamine; bk-MBDP; bk-methyl-K).

8. Unless specifically listed in another schedule, coca leaves, cocaine base or free base, or a salt, compound, derivative, isomer or preparation thereof which is chemically equivalent or identical to such substances, and any quantity of material, compound, mixture or preparation which contains coca leaves, cocaine base or cocaine free base or its isomers or any of the salts of cocaine, except decocainized coca leaves or extractions which do not contain cocaine or ecgonine.

9. Unless specifically listed in another schedule, Tetrahydrocannabinols (natural or synthetic equivalents of substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity such as the following:

Delta 9 cis or trans tetrahydrocannabinol, and their optical isomers, also known as Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers;

Delta 8 cis or trans tetrahydrocannabinol, and their optical isomers, also known as Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers;

Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers;

Tetrahydrocannabinols contained in the genus Cannabis or in the resinous extractives of the genus Cannabis;

Synthetic equivalents of tetrahydrocannabinol substances or synthetic substances, derivatives and their isomers with a similar chemical structure; and

Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered).

10. Unless specifically listed in another schedule and except as otherwise provided in subsection 11, any material, compound, mixture or preparation which contains any quantity of CBD (natural or synthetic equivalents of the substances contained in the plant or in the resinous extractives of Cannabis sp. or synthetic substances, derivatives and their isomers with similar chemical structure and pharmacological activity).

11. A drug product which:

(a) Has been approved by the United States Food and Drug Administration;

(b) Contains CBD derived from any plant in the genus Cannabis or the resinous extractives thereof; and

Ê is not a controlled substance.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-82; A 10-26-83; 9-29-87; 8-10-89; 9-11-91; 7-1-92; 1-10-94; R024-98, 4-17-98; R110-00, 10-25-2000; R001-01, 11-1-2001; R121-04, 8-25-2004; R181-07, 4-17-2008; R156-10, 5-5-2011; R065-11, 2-15-2012; R023-12, 5-30-2012; R187-12, 2-20-2013; R015-13, 10-23-2013; R015-14, 10-24-2014; R142-14, 12-21-2015; R080-15 & R011-17, 10-31-2017; R093-19, 6-8-2020; R090-20, 12-29-2020; R143-20, 4-14-2021; R023-21, 12-22-2021; R006-22, 6-13-2022; R050-22, 9-28-2022)

NAC 453.520 Schedule II. (NRS 453.146, 453.2182, 639.070)

1. Schedule II consists of the drugs listed in this section, by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis, is hereby enumerated in schedule II:

(a) Opium and opiate, and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and their respective salts, but including:

Codeine;

Diprenorphine;

Ethylmorphine;

Etorphine hydrochloride;

Granulated opium;

Hydrocodone;

Hydrocodone combination product (meaning any product that contains hydrocodone in combination with any other active ingredient);

Hydromorphone;

Metopon;

Morphine;

Opium extracts;

Opium fluid;

Powdered opium;

Raw opium;

Oxycodone;

Oxymorphone;

Thebaine; and

Tincture of opium.

(b) Any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (a) if they do not include the isoquinoline alkaloids of opium.

(d) Cocaine hydrochloride salt prepared by a registered chemical or pharmaceutical manufacturer of the Drug Enforcement Administration of the Department of Justice which is properly labeled, including lot numbers, and is available for medicinal purposes through a distribution system approved by the Drug Enforcement Administration.

(e) Benzolyecgonine or ecgonine.

(f) Concentrate of poppy straw (meaning the crude extract of poppy straw in either liquid, solid or powder form and containing the phenanthrene alkaloids of the opium poppy).

3. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation (dextrorphan and levopropoxyphene excepted), are hereby enumerated on schedule II:

Alfentanil;

Alphaprodine;

Anileridine;

Bezitramide;

Bulk dextropropoxyphene (in nondosage forms);

Carfentanil;

Dihydrocodeine;

Diphenoxylate;

Fentanyl;

Isomethadone;

Levo-alphacetylmethadol (some trade or other names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM);

Levomethorphan;

Levorphanol;

Metazocine;

Methadone;

Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;

Pethidine (meperidine);

Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

Pethidine-Intermediate-B, ethyl-4-phenylpiperdine-4-carboxylate;

Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

Phenazocine;

Piminodine;

Racemethorphan;

Racemorphan;

Ramifentanil;

Sufentanil; or

Tapentadol.

4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system is hereby enumerated on schedule II:

(a) Amphetamine, its salts, optical isomers and salts of optical isomers;

(b) Phenmetrazine and its salts;

(c) Unless specifically excepted, any preparation which contains any quantity of methamphetamine, including its salts, isomers and salts of isomers, prepared by a registered chemical or pharmaceutical manufacturer of the Drug Enforcement Administration of the Department of Justice, which is properly labeled, including lot numbers, and is available for medicinal purposes through a distribution system approved by the Drug Enforcement Administration;

(d) Methylphenidate; or

(e) Lisdexamfetamine.

5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation, is hereby enumerated on schedule II:

Amobarbital;

Glutethimide;

Pentobarbital; or

Secobarbital.

6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances is hereby enumerated on schedule II:

(a) Immediate precursors to phencyclidine (PCP):

1-Phenylcyclohexylamine; or

1-piperidinocyclohexanecarbonitrile (PCC).

(b) Immediate precursors to amphetamine and methamphetamine:

Phenylacetone (some trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone).

4-anilino-N-phenethylpiperidine (some trade or other names: 4-ANPP; ANPP; 4-anilino-N-phenethyl-4-piperidine; despropionyl fentanyl; 4-Aminophenyl-1-phenethylpiperidine; N-phenyl-1-(2-phenylethyl)-4-piperidinamine).

7. Any material, compound, mixture or preparation which contains any quantity of Nabilone (commonly referred to as: (+)-trans-3-(1,1-dimethylheptyl)-6, 6a, 7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H- dibenzol[b,d]pyran-9-one) is hereby enumerated on schedule II.

8. Dronabinol oral solution in a drug product approved by the United States Food and Drug Administration (some trade or other names: (6aR,10aR)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-penthyl-6H-dibenzo[b,d]-pyran-1-ol; (-)-delta-9-trans-tetrahydrocannabinol; Syndros) is hereby enumerated on schedule II.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-83; A 10-26-83; 1-15-87; 9-29-87; 8-10-89; 9-11-91; 7-1-92; 1-10-94; R153-99, 3-1-2000; R002-01, 11-1-2001; R157-10, 5-5-2011; R137-14, 12-22-2014; R001-19, 10-30-2019; R084-20, 11-2-2020)

NAC 453.530 Schedule III. (NRS 453.146, 453.2182, 639.070)

1. Schedule III consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation, is hereby enumerated on schedule III, including:

(a) Those compounds, mixtures or preparations in dosage unit form containing any substance listed in schedule II which has a stimulant effect on the central nervous system, which compounds, mixtures or preparations were listed on August 25, 1971, as excepted compounds under the regulations of the Drug Enforcement Administration of the United States Department of Justice, and any other drug of the same quantitative composition as a drug shown on the list or which is the same except that it contains a lesser quantity of controlled substances;

(b) Benzphetamine;

(d) Clortermine; or

(e) Phendimetrazine.

Ê For the purposes of this subsection, “isomer” includes the optical, position or geometric isomer.

3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system is hereby enumerated on schedule III:

(a) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof;

(b) Chlorhexadol;

(d) Lysergic acid;

(e) Lysergic acid amide;

(f) Methyprylon;

(g) Sulfondiethylmethane;

(h) Sulfonethylmethane;

(i) Sulfonmethane;

(j) Any compound, mixture or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients, which are not listed in any schedule;

(k) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs approved by the Food and Drug Administration of the United States Department of Health and Human Services for marketing only as a suppository; or

(l) Tiletamine and zolazepam or any salt thereof. (Some trade or other names for a tiletamine-zolazepam combination product: Telazol. Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e][1,4]-diazepin-7(1H)-one, flupyrazapon).

4. Nalorphine is hereby enumerated on schedule III.

5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs or their salts, calculated as the free anhydrous base or alkaloid, in quantities is hereby enumerated on schedule III:

(a) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(b) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(c) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(d) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(e) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; or

(f) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

6. Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of:

(a) N-methylephedrine, its optical isomers, salts and salts of optical isomers;

(b) Hydriodic acid; or

Ê are, as immediate precursors, controlled, the control of which is necessary to prevent, curtail or limit the manufacture of the controlled substances methamphetamine and N, N-dimethylamphetamine.

7. Except as otherwise provided in subsections 8 and 9, or specifically excepted or listed in another schedule, any material, compound, mixture or preparation containing any quantity of anabolic steroids, including their salts, isomers, esters and salts of isomers, whenever the existence of such salts of isomers is possible within the specific chemical designation, is hereby enumerated on schedule III:

(a) Androisoxazole;

(b) Androstenediol;

(d) Bolasterone;

(e) Boldenone;

(f) Chlormethandienone;

(g) Clostebol;

(h) Chorionic gonadotropin (HCG);

(i) Dehydrochlormethyltestosterone;

(j) Dihydromesterone;

(k) Drostanolone;

(l) Ethylestrenol;

(m) Fluoxymesterone;

(n) Formebolone;

(o) Formyldienolone;

(p) 4-Hydroxy-19-nortestosterone;

(q) Mesterolone;

(r) Methandrenone;

(s) Methandriol;

(t) Methandrostenolone;

(u) Methenolone;

(v) 17-Methyltestosterone;

(w) Methyltrienolone;

(x) Mibolerone;

(y) Nandrolone;

(z) Norbolethone;

(aa) Norethandrolone;

(bb) Normethandrolone;

(cc) Oxandrolone;

(dd) Oxymesterone;

(ee) Oxymetholone;

(ff) Quinbolone;

(gg) Stanolone;

(hh) Stanozolol;

(ii) Stenbolone;

(jj) Testolactone;

(kk) Testosterone; or

(ll) Trenbolone.

8. Any anabolic steroid or chorionic gonadotropin (HCG) described in subsection 7 which is used solely for implantation or injection in cattle or any other nonhuman species and is approved by the Food and Drug Administration for that use is not a controlled substance.

9. The following classifications are not controlled substances for the purposes of this section:

(a) Oral combinations containing therapeutic doses of estrogen and androgen;

(b) Parenteral preparations containing therapeutic doses of estrogen and androgen;

(d) Vaginal preparations.

10. Ketamine, including its salts, isomers and salts of isomers, is hereby enumerated on schedule III.

11. Synthetic Dronabinol in sesame oil encapsulated in a soft gelatin capsule in a drug product approved by the Food and Drug Administration (some trade or other names: (6aR-trans)-6a,7,8,10a-tetrahydro-6; 6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran- 1-ol; (-)-delta-9-(trans)-tetrahydrocannabinol; Marinol) is hereby enumerated on schedule III.

12. Gamma-hydroxybutyrate prepared by a registered pharmaceutical manufacturer of the Food and Drug Administration which is properly labeled, including lot numbers, and is available for medicinal purposes through a distribution system approved by the Food and Drug Administration is hereby enumerated on schedule III.

13. Human growth hormone (HGH) is hereby enumerated on schedule III.

14. Any material, compound, mixture or preparation containing buprenorphine, including its salts, is hereby enumerated on schedule III.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-82; A 10-26-83; 7-2-84; 8-10-89; 2-6-90; 9-11-91; 10-1-93; 1-10-94; 7-17-96; 11-14-97; R153-99, 3-1-2000; R003-01, 11-1-2001; R163-01, 12-17-2001; R141-03, 4-8-2004; R041-07 & R047-07, 12-4-2007; R181-07, 4-17-2008; R218-08, 10-27-2009; R123-09, 1-28-2010; R016-14, 10-24-2014; R137-14, 12-22-2014; R013-17, 10-31-2017)

NAC 453.540 Schedule IV. (NRS 453.146, 453.2182, 639.070)

1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.

2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities:

(a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or

(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy-butane).

3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

Alprazolam;

Barbital;

Bromazepam;

Butorphanol;

Camazepam;

Carisoprodol;

Chloral betaine;

Chloral hydrate;

Chlordiazepoxide;

Clobazam;

Clonazepam;

Clorazepate;

Clotiazepam;

Cloxazolam;

Daridorexant;

Delorazepam;

Diazepam;

Dichloralphenazone;

Eluxadoline;

Estazolam;

Ethchlorvynol;

Ethinamate;

Ethyl loflazepate;

Fludiazepam;

Flunitrazepam;

Flurazepam;

Halazepam;

Haloxazolam;

Ketazolam;

Lemborexant;

Loprazolam;

Lorazepam;

Lorcaserin;

Lormetazepam;

Mebutamate;

Medazepam;

Meprobamate;

Methohexital;

Methylphenobarbital (mephobarbital);

Midazolam;

Nimetazepam;

Nitrazepam;

Nordiazepam;

Oxazepam;

Oxazolam;

Paraldehyde;

Petrichloral;

Phenobarbital;

Pinazepam;

Prazepam;

Quazepam;

Remimazolam;

Suvorexant;

Temazepam;

Tetrazepam;

Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol);

Triazolam;

Zaleplon;

Zolpidem; or

Zopiclone.

4. Any material, compound, mixture or preparation which contains any quantity of fenfluramine, including, without limitation, its salts, isomers and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible, is hereby enumerated on schedule IV. For the purposes of this subsection, “isomer” includes, without limitation, the optical, position or geometric isomer.

5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV:

Cathine ((+)-norpseudoephedrine);

Diethylpropion;

Fencamfamin;

Fenproporex;

Mazindol;

Mefenorex;

Modafinil;

Pemoline (including organometallic complexes and chelates thereof);

Phentermine;

Pipradrol;

Sibutramine; or

SPA ((-)-dimethylamino-1,2,diphenylethane).

6. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pentazocine, including, without limitation, its salts, is hereby enumerated on schedule IV.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-82; A 10-26-83; 9-11-91; 1-10-94; R025-98, 4-17-98; R201-99, 3-1-2000; R004-01, 11-1-2001; R188-01, 3-4-2002; R040-04, 7-13-2004; R181-07, 4-17-2008; R158-10, 5-5-2011; R133-14, 6-26-2015; R004-15, 8-10-2015; R079-15, 4-4-2016; R150-16, 2-7-2020; R024-21, 12-22-2021; R170-22, 9-28-2022)

NAC 453.550 Schedule V. (NRS 453.146, 453.2182, 639.070)

1. Schedule V consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated.

2. Any compound, mixture or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base alkaloid, containing one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone, in quantities:

(a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams; or

(f) Not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

3. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pyrovalerone having a stimulant effect on the central nervous system, including their salts, isomers and salts of isomers.

4. Unless specifically excepted or excluded or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of pregabalin having a depressant effect on the central nervous system, including their salts, isomers and salts of isomers.

5. Brivaracetam.

6. Lacosamide.

(Added to NAC by Bd. of Pharmacy, eff. 6-25-82; A 10-26-83; 9-11-91; 1-10-94; R181-07, 4-17-2008; R123-09, 1-28-2010; R159-10, 5-5-2011; R198-18, 6-26-2019; R149-16, 2-7-2020; R090-20, 12-29-2020)

PROGRAM TO RESEARCH THERAPEUTIC EFFECTS OF MARIJUANA

NAC 453.740 Protocols of research and treatment. (NRS 439.200)

1. The State Board of Health will:

(a) Approve protocols of research and treatment; and

(b) Approve changes in protocols of research and treatment,

Ê for the program to research the therapeutic effects of marijuana.

2. The program must be conducted in accordance with the most recent protocols approved by the State Board of Health.

[Bd. of Health, Therapeutic Effects of Marijuana, eff. 6-24-80]